A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma

Most anticancer drugs entering clinical trials fail to achieve approval from the US FDA. Drug development is hampered by the lack of preclinical models with therapeutic predictive value. Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its appl...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sivanand, Sharanya, Peña-Llopis, Samuel, Zhao, Hong, Kucejova, Blanka, Spence, Patrick, Pavia-Jimenez, Andrea, Yamasaki, Toshinari, McBride, David J., Gillen, Jessica, Wolff, Nicholas C., Morlock, Lorraine, Lotan, Yair, Raj, Ganesh V., Sagalowsky, Arthur, Margulis, Vitaly, Cadeddu, Jeffrey A., Ross, Mark T., Bentley, David R., Kabbani, Wareef, Xie, Xian-Jin, Kapur, Payal, Williams, Noelle S., Brugarolas, James
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570965/
https://ncbi.nlm.nih.gov/pubmed/22674553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3003643
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky